Erratum: Downregulation of propranolol-sensitive β-adrenoceptor signaling after inhibition of nitric oxide synthesis (British Journal of Pharmacology (2006) 147 (755-764) DOI: 10.1038/sj.bjp.0706675);Downregulation of propranolol-sensitive β-adrenoceptor signaling after inhibition of nitric oxide synthesis

British Journal of Pharmacology

Volumn 147, Issue 7, 2006, Pages 755-764

  Whalen, Erin J ^a,b,d   Bates, James N ^a   Johnson, Alan Kim ^a   Lewis, Stephen J ^c  

^a UNIVERSITY OF IOWA   (United States)

^b E11 SSH   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Isoprenaline; Nitric oxide; Rats; Tachycardia; Vasodilation; Adrenoceptors

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; ISOPRENALINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PENTOBARBITAL; PHENYLEPHRINE; PROPRANOLOL DERIVATIVE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; HEART RATE; HEMODYNAMICS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TACHYCARDIA; UPREGULATION; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; VASODILATATION;

EID: 33645547036     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706870     Document Type: Erratum

References (40)

1. BALLIGAND, J-L., KELLY, R.A., MARSDEN, P.A., SMITH, T.W. & MICHEL, T. (1993). Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc. Natl. Acad. Sci. U.S.A., 90, 347-351.
2. BATENBURG, W.W., DE VRIES, R., SAXENA, P.R. & DANSER, A.H. (2004a). L-S-nitrosothiols: endothelium-derived hyperpolarizing factors in porcine coronary arteries? J. Hypertens., 22, 1927-1936.
3. BATENBURG, W.W., POPP, R., FLEMING, I., DE VRIES, R., GARRELDS, I.M., SAXENA, P.R. & DANSER, A.H. (2004b). Bradykinin-induced relaxation of coronary microarteries: S-nitrosothiols as EDHF? Br. J. Pharmacol., 142, 125-135.
4. 1-adrenoceptors in human myocardium. J. Pharmacol. Exp. Ther., 300, 794-801.
5. CLAING, A., LAPORTE, S.A., CARON, M.G. & LEFKOWITZ, R.J. (2002). Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Prog. Neurobiol., 66, 61-79.
6. 3-adrenoceptors and atrial receptors mediating tachycardia. Br. J. Pharmacol., 126, 1018-1024.
7. 3 receptor? J. Pharmacol. Exp. Ther., 272, 446-451.
8. DANSER, A.H., DE VRIES, R., SCHOEMAKER, R.G. & SAXENA, P.R. (1998). Bradykinin-induced release of nitric oxide by the isolated perfused rat heart: importance of preformed pools of nitric oxide-containing factors. J. Hypertens., 16, 239-244.
9. DAVISSON, R.L., TRAVIS, M.D., BATES, J.N. & LEWIS, S.J. (1996). Hemodynamic effects of L- and D-S-nitrosocysteine in the rat: stereoselective S-nitrosothiol recognition sites. Circ. Res., 79, 256-262.
10. 3-adrenoceptor: the search for a physiological function. Trends Pharmacol. Sci., 15, 3-7.
11. 3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J. Clin. Invest., 102, 1377-1384.
12. HAN, X., SHIMONI, Y. & GILES, W.R. (1994). An obligatory role for nitric oxide in autonomic control of mammalian heart rate. J. Physiol., 476, 309-314.
13. HARDEN, T.K. (1983). Agonist-induced desensitization of the β-adrenergic receptor-linked adenylate cyclase. Pharmacol. Rev., 35, 5-32.
14. HAYWOOD, J.R., SHAFFER, R.A., FASTENOW, C., FINK, G.D. & BRODY, M.J. (1981). Regional blood flow measurement with pulsed Doppler flowmeter in conscious rat. Am. J. Physiol., 241, H273-H278.
15. IGNARRO, L.J. (1990). Nitric oxide: a novel signal transduction mechanism for transcellular communication. Hypertension, 16, 477-483.
16. KAUMANN, A.J. (1996). (-)CGP 12177-induced increase of human atrial contraction through a putative third β-adrenoceptor. Br. J. Pharmacol., 117, 93-98.
17. 4- adrenoceptor pharmacology. Naunyn-Schmiedeberg's Arch. Pharmacol., 363, 87-93.
18. KOHOUT, T.A. & LEFKOWITZ, R.J. (2003). Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. Mol. Pharmacol., 63, 9-18.
19. LACOLLEY, P.J., LEWIS, S.J. & BRODY, M.J. (1991). Role of the sympathetic nerve activity in the generation of vascular nitric oxide in urethane anesthetized rats. Hypertension, 17, 881-887.
20. LEFKOWITZ, R.J. & WHALEN, E.J. (2004). Beta-arrestins: traffic cops of cell signaling. Curr. Opin. Cell Biol., 16, 162-168.
21. LEFKOWITZ, R.J. (2004). Historical review: a brief history and personal retrospective of seven-transmembrane receptors. Trends Pharmacol. Sci., 25, 413-422.
22. LEWIS, S.J., GRAVES, J.E., BATES, J.N. & KOOY, N.W. (2005a). Peroxynitrite elicits dysfunction of stereoselective S-nitrosocysteine recognition sites. J. Cardiovasc. Pharmacol., 46, 637-645.
23. LEWIS, S.J., HOQUE, A. & BATES, J.N. (2005b). Differentiation of L- and D-S-nitrosothiol recognition sites. J. Cardiovasc. Pharmacol., 46, 660-671.
24. LEWIS, S.J., HOQUE, A., WALTON, T.M. & KOOY, N.W. (2005c). Potential role of nitration and oxidation reactions in the effects of peroxynitrite on the function of β-adrenoceptor sub-types in the rat. Eur. J. Pharmacol., 518, 187-194.
25. MYERS, P.R., MINOR JR, R., GUERRA JR, R., BATES, J.N. & HARRISON, D.G. (1990). Vasorelaxant properties of the endothelium-derived relaxing factor more closely resembles S-nitrosocysteine than nitric oxide. Nature, 345, 161-163.
26. 1-adrenergic receptor-mediated vasoconstriction and ligand binding in pulmonary artery. Am. J. Physiol., 290, L136-L143.
27. PROBST, W.C., SNYDER, L.A., SCHUSTER, D.I., BROSIUS, J. & SEALFON, S.C. (1992). Sequence alignment of the G-protein coupled receptor superfamily. DNA Cell Biol., 11, 1-20.
28. ROSENBLUM, W.I. (1992). Endothelium-derived relaxing factor in brain blood vessels is not nitric oxide. Stroke, 23, 1527-1535.
29. SEINO, S. & SHIBASAKI, T. (2005). PKA-dependent and PKA-independent pathways for cAMP-regulated exocytosis. Physiol. Rev., 85, 1303-1342.
30. STAMLER, J.S., SINGER, D.J. & LOSCALZO, J. (1992). Biochemistry of nitric oxide and its redox-activated forms. Science, 258, 1898-1902.
31. STAMLER, J.S., TOONE, E.J., LIPTON, S.A. & SUCHER, N.J. (1997). S)NO signals: Translocation, regulation, and a consensus motif. Neuron, 18, 691-696.
32. 2-receptors. Eur. J. Pharmacol., 382, 207-210.
33. WHALEN, E.J., JOHNSON, A.K. & LEWIS, S.J. (1998). Blockade of β-adrenoceptors up-regulates cAMP signal transduction in vivo. Eur. J. Pharmacol., 355, 189-193.
34. WHALEN, E.J., JOHNSON, A.K. & LEWIS, S.J. (1999a). Effects of nitric oxide synthase inhibition on sympathetically-mediated tachycardia in vivo. Eur. J. Pharmacol., 365, 217-223.
35. WHALEN, E.J., JOHNSON, A.K. & LEWIS, S.J. (1999b). Tachyphylaxis to PACAP-27 after inhibition of NO synthesis: a loss of adenylate cyclase activation. Am. J. Physiol., 277, R1453-R1461.
36. WHALEN, E.J., JOHNSON, A.K. & LEWIS, S.J. (1999c). Hemodynamic actions of systemically injected pituitary adenylate cyclase activating polypeptide-27 in the rat. Eur. J. Pharmacol., 365, 205-215.
37. WHALEN, E.J., JOHNSON, A.K. & LEWIS, S.J. (2000). Adrenoceptor dysfunction after inhibition of NO synthesis. Hypertension, 36, 376-382.
38. WHALEN, E.J., TRAVIS, M.D., JOHNSON, A.K. & LEWIS, S.J. (1999d). Rapid tachyphylaxis to the hemodynamic effects of PACAP-27 after inhibition of nitric oxide synthesis. Am. J. Physiol., 276, H2117-H2126.
39. WHITE, R.E., LEE, A.B., SHCHERBATCO, A.D., LINCOLN, T.M., SCHONBRUNN, A. & ARMSTRONG, D.L. (1993). Potassium channel stimulation by natriuretic peptides through cGMP-dependent dephosphorylation. Nature, 361, 263-266.
40. YOUNG, L.H., LI, J., BARON, S.J. & RUSSELL, R.R. (2005). AMP-activated protein kinase: a key stress signaling pathway in the heart. Trends Cardiovasc. Med., 15, 110-118.